Company / Operating Cash Flow
MoonLake Immunotherapeutics Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$196.0M
FY2025
5-year range
-$196.0M / -$35.2M
FY2021-FY2025
Trend
-68.1%
vs FY2024
Sector context
#170 of 216
Health Care
What the data says
MoonLake Immunotherapeutics's operating cash flow of -$196M is lower than 79% of companies in the Health Care sector (FY2025). Declined from -$43M to -$196M over the past 2 years.
Based on SEC 10-K filings.
-$196M in FY2025.
Declined from -$43M to -$196M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 216This company -$196.0M Sector average $658.7M
▼
-129.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 68.1% year-over-year.
- Ranks #170 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$196.0M | -68.1% |
| FY2024 | -$116.6M | -172.5% |
| FY2023 | -$42.8M | +23.5% |
| FY2022 | -$55.9M | -58.9% |
| FY2021 | -$35.2M | -11007.1% |
| FY2020 | -$316.7K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026